Madrigal Pharmaceuticals (MDGL) Stock: Buy, Sell, or Hold?

MDGL - Madrigal Pharmaceuticals, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$476.91
-10.81 (-2.22%) ▼
5d: -4.56%
30d: -12.76%
90d: -11.14%
WAIT
LOW Confidence
Protect Your MDGL Gains
Analysis Updated: Oct 8, 2026 12:00 AM ET
Earnings: Nov 03, 2026 24d

Get Alerted When MDGL Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 MIXED SIGNALS: MDGL shows conflicting indicators. Wait for confirmation before entering.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$337.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$209.35
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: MDGL is currently trading at $476.91, which is considered oversold relative to its 30-day fair value range of $501.94 to $539.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 49.5) compared to its historical average (90.0). Remarkably, the market is currently pricing in an annual earnings decline of 18.1% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, MDGL is showing sideways momentum. The price is currently testing key support at $466.06. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: MDGL scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $682.11 (+43.0%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $501.94 - $539.77
Company Quality Score 45/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 65.4%

Protect Your Profits

Holding MDGL? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • BULLISH: Price oversold vs 30-day range
  • BULLISH: Options cheap (IV 0th percentile)
  • BEARISH: Weak technical setup (27/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 43.0% below Wall St target ($682.11)
  • WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $501.94 - $539.77
Current vs Trading Range OVERSOLD
Expected Move (7 Days) ±$32.45 (6.8%)

Support & Resistance Levels

Support Level $466.06
Resistance Level $525.00
Current Trend Sideways
Technical data as of Oct 8, 2026

Fundamental Context

Forward P/E (Next Year Est.) 49.55
Wall Street Target $682.11 (+43.0%)
Revenue Growth (YoY) 71.2%
Profit Margin -25.3%
Valuation Discount vs History -18.1% cheaper
PE vs Historical 49.6 vs 90.0 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -18.1% (market-implied from PE analysis)
1-Year Target $429.22 (-10%)
2-Year Target $386.30 (-19%)
3-Year Target $347.67 (-27%)
3-Yr Target (if PE normalizes) (PE: 50→90) $631.50 (+32%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 49.5 to 90.0
Stabilization Target: $866.25 (+81.6%)
PE Expansion Potential: +81.6%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: October 08, 2026 9:09 PM ET
Data refreshes hourly during market hours. Next update: 10:09 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for MDGL.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
DNLI
Denali Therapeutics Inc
STRONG BUY
20 analysts
$36 49 HOLD
SRRK
Scholar Rock Holding Corp
STRONG BUY
18 analysts
$70 47 HOLD
MIRM
Mirum Pharmaceuticals Inc
STRONG BUY
14 analysts
$146 60 BUY
WVE
Wave Life Sciences Ltd
STRONG BUY
19 analysts
$18 42 HOLD
SGMT
Sagimet Biosciences Inc.…
STRONG BUY
12 analysts
$28 72 BUY

Advanced MDGL Option Strategies

Professional options setups generated by AI based on today's MDGL price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for MDGL

MDGL Technical Chart MDGL Price Prediction MDGL Earnings Date Why is MDGL Moving Today? MDGL Investment Advisor MDGL Fair Price Analyzer MDGL Options Advisor MDGL Options Chain MDGL Options Analysis MDGL Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals